Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.